{
  "symbol": "ABBV",
  "year": 2022,
  "period": "Y2022",
  "curated_text": "Symbol: ABBV. Year: 2022. Period: Y2022. ReportType: K10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: Humira, Botox, FDA, the Federal Food, Drug, FFDCA, the Public Health Service Act. Context excerpt: Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In addition, in the past few years, a number of other companies have started to develop, have successfully developed and/or are currently marketing products that are being positioned as competitors to Botox. The search for technological innovations in pharmaceutical products is a significant aspect of competition. The introduction of new products by competitors and changes in medical practices and procedures can result in product obsolescence. Price is also a competitive factor. In addition, the s",
  "competition_summary": [
    {
      "competitor": "Humira",
      "mentions": 2,
      "context": "Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In"
    },
    {
      "competitor": "Botox",
      "mentions": 1,
      "context": "Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In"
    },
    {
      "competitor": "the Federal Food, Drug",
      "mentions": 1,
      "context": "Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In"
    },
    {
      "competitor": "FFDCA",
      "mentions": 1,
      "context": "Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In"
    },
    {
      "competitor": "the Public Health Service Act",
      "mentions": 1,
      "context": "Competition The markets for AbbVie's products are highly competitive. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market and sell proprietary pharmaceutical products, therapies 5 | 2021 Form 10-K and biologics. For example, Humira competes with anti-TNF products, JAK inhibitors and other competitive products intended to treat a number of disease states and Mavyret/Maviret competes with other available HCV treatment options. In"
    }
  ]
}